Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial

With significant upside potential, Spyre Therapeutics Inc. (NASDAQ:SYRE) secures a spot on our list of the 10 Best Debt Free Small Cap Stocks to Buy Now.

On September 15, 2025, Spyre Therapeutics Inc. (NASDAQ:SYRE) announced the enrollment of the first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases. This randomized study will assess the company’s lead antibody program in patients who showed no response to standard treatments.

As this is its second Phase 2 program, Spyre Therapeutics Inc. (NASDAQ:SYRE) expects initial data in 2026, with several proof-of-concept readouts planned over the next two years.

Spyre Therapeutics Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company, develops therapies for inflammatory bowel disease. It is one of the Best Debt Free Stocks.

While we acknowledge the potential of SYRE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SYRE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.